Short answer
Mineralys Therapeutics, Inc. (MLYS) filed an 8-K current report with the SEC on March 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q4 and full-year FY2025 results released March 12, 2026: full figures in Exhibit 99.1.
Mineralys Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q4 and full-year FY2025 results released March 12, 2026: full figures in Exhibit 99.1
- Filing covers period ended December 31, 2025 for clinical-stage biopharma MLYS
- Results disclosed under Reg FD "furnished" (not "filed") status: limits legal liability but carries same market-moving weight
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Mineralys Therapeutics, Inc. 8-K filings
Get the next MLYS 8-K as it lands
Follow MLYS for push alerts, or ask the research agent what this filing means.